 Gal-NAC lipid nanoparticles can be used to deliver therapeutics to patients with homozygous familial hypercholesterole, HoFH, who are deficient in the low-density lipoprotein receptor, LDLR. This study showed that the addition of a Gal-NAC-based azuloblacoprotein receptor ligant to the nanoparticle surface increased liver editing from 5% to 61% while minimising off-target effects. The nanoparticles were also effective in wild-type monkeys, resulting in durable blood A and GPT-L-3 protein reduction up to 89%. This article was authored by Lisa N. Kasiewicz, Shovik Bisfoss, Aaron Beech, and others.